Yahoo
NasdaqGM - Delayed Quote USD

Larimar Therapeutics, Inc. (LRMR)

3.8300 0.0000 (0.00%)
At close: September 4 at 4:00:01 PM EDT
3.8500 +0.0200 (+0.52%)
After hours: September 4 at 7:30:03 PM EDT
Trade LRMR on Coinbase
Chart Range Bar
Loading chart for LRMR
  • Previous Close 3.8300
  • Open 3.8100
  • Bid 2.9500 x 200
  • Ask 5.2900 x 200
  • Day's Range 3.7900 - 3.8500
  • 52 Week Range 2.7150 - 6.4200
  • Volume 391,889
  • Avg. Volume 1,859,411
  • Market Cap (intraday) 397.872M
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) --
  • EPS (TTM) -2.0100
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 14.30

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

www.larimartx.com

71

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LRMR
0.52%
S&P 500 (^GSPC)
12.75%

1-Year Return

LRMR
1.03%
S&P 500 (^GSPC)
18.71%

3-Year Return

LRMR
0.00%
S&P 500 (^GSPC)
70.93%

5-Year Return

LRMR
74.10%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -32.78M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-60M
-40M
-20M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

5.00
14.30 Average
3.8300 Current
26.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/5/2026
Analyst Wedbush
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 12 -> 11

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -70.96%

  • Return on Equity (ttm)

    -139.63%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -172.6M

  • Diluted EPS (ttm)

    -2.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    156.27M

  • Total Debt/Equity (mrq)

    3.89%

  • Levered Free Cash Flow (ttm)

    -94.18M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: